The silkworm holds a treasure beyond the luxury
of exquisite textiles. It’s called serrapeptase (AKA Serratio Peptidase or SP,
DanzenTM, AniflazymTM SerraZymeTM), a powerful protolytic enzyme that dissolves
all nonliving tissue, including blood clots, cysts, arterial plaque and
inflammation in all forms.
The mighty enzyme offers a viable alternative to salicylates (such as aspirin),
ibuprofen, and NSAIDS as well as steroids—a boon for those suffering with
rheumatoid arthritis and a wide array of other autoimmune diseases that affect
the inflammatory response, including ulcerative colitis, psoriasis, uveitis,
allergies, and some forms of cancer.
While steroidal and nonsteroidal antiinflammatory drugs may offer temporary,
symptomatic relief from pain, swelling and inflammation, they may also be
immunosuppressive and known to hold dangerous side effects. Serrapeptase, on the
other hand, eases pain and swelling with no inhibitory effects on prostaglandins
and no gastrointestinal side effects. The immunologically active enzyme is
completely bound to the alpha 2 macroglobulin in biological fluids.
The physiologic agent is isolated from the microorganism Serratia E15, an enzyme
naturally present in the silkworm intestine which allows the emerging moth to
dissolve its cocoon. Clinical use of serrazyme as an antiinflammatory in
Europe and Asia spans over twenty five years. Treatment includes chronic
sinusitis, elimination of bronchopulmonary secretions (the enzyme breaks down
protein fibers, allowing mucous to thin), sprains and torn ligaments, and other
traumatic injuries, idiopathic edema, as well as postoperative inflammation.
Studying postoperative swelling and pain reduction of the upper ankle joint, a
test was carried out in 3 randomized groups of 66 patients, each with fresh
rupture of the lateral ligament treated surgically between December 1986 and
April 1987. The group receiving SP saw a 50% decrease in swelling on the third
postoperative day. Decreased pain, for the most part, correlated with reduction
in swelling. The SP group became rapidly pain-free. The two control groups,
using traditional elevation of the leg, bed rest, with and without applications
of ice, had no reduction in swelling at that time. (Esch PM, Gerngross H, Fabian
A, Fortachr Med,107(4):67.8, 71-2 1989 Feb 10)
Another multi-centre, double-blind, placebo-controlled trial was carried out to
investigate the clinical efficacy of SP in 174 patients who underwent
Caldwell-Luc antrotomy for chronic empyema. Eighty-eight patients received 10 mg
SP 3 times the day before surgery, once the night of the operation and 3 times
daily for 5 days after surgery; the other 86 received a placebo. The
degree of swelling in the serrapeptase-treated patients was significantly less
than that in the placebo-treated patients at every point of observation after
surgery up to the 5th day. Maximal buccal swelling throughout all the
postoperative points of observation was also significantly smaller in size in
the SP group. No side effects were reported. (Tachibana M, Mizukosi 0, Harada Y,
Kawamoto K, Nakai Y. Source: Pharmathera-peutica, 3(8):526-30 1984).
Additionally, SP in a 70 patient, double-blind controlled trial treating breast
engorgement saw SP improve breast pain and swelling in significant numbers of
the treatment group with no adverse reactions. (Kee WH, Tan SL; Lee V, Salmon YM
.Singapore Med J, 30(I) :48-54 1989 Feb)
Researchers in Germany have used SP to treat atherosclerosis since serrapeptase
helps to digest atherosclerotic plaque without harming healthy cells lining the
arterial wall. The hardened, narrow arterial wall is considered the
cumulative result of microscopic trauma with inflammation occurring in the
presence of oxidized lipids—serrapeptase works on both inflammation as well as
dissolving the avital plaque. Unlike cholesterol-blocking drugs, serapeptase
clears the avital tissue from the arterial wall without interfering with
cholesterol synthesis. In fact, when taking serrapeptase, cholesterol levels may
rise as it is dissolved from the arteries to be eliminated from the body
(cholesterol in its pure state is an antioxidant and a necessary component of
steroidal hormones and the major organ systems in the body).
Medications blocking cholesterol biosynthesis hold the threat of liver, eye,
lung and other soft tissue damage. While studies with SP in the treatment of
coronary artery disease are relatively new; some literature reports SP as being
superior to, and faster than, chelation.
The late German physician Dr. Hans Nieper used serrapeptase to treat arterial
blockage in his coronary patients, reporting that serrapeptase also dissolves
blood clots, and causes varicose veins to shrink or diminish. Dr.Nieper told of
a woman scheduled for hand amputation and a man scheduled for bypass surgery;
both recovered quickly without surgery after treatment with serrapeptase.
In addition, widespread use has included fibrocystic breast disease and carpal
tunnel syndrome.
The enzyme is also used to facilitate the therapeutic effect of antibiotics in
the treatment of infection. In urology serrapeptase has been successfully
employed to treat cystitis and epididymitis.
Serrapeptase is available as SerraZyme in 10 mg enterically coated tablets that
are equivalent to 20,000 IU activity.
Recommended Usage: For inflammation is 1 tablets three times daily on an empty
stomach. For arterial blockage 1 tablets twice daily or as directed by your
health professional. (In acute conditions, your health care professional may
recommend that you take 2 tablets on an empty stomach 6 times per day).
Copyright, Julia Busch 2000
Reprinted from the "So Young" holistic health, antiaging newsletter.
NEW INFO ON SP-ZYME BRAND: Click here...
Wellness Directory
|
